ReviewMolecular diagnosis & therapy2026
The Role of Non-coding RNAs in Connective Tissue Diseases: Diagnostic and Therapeutic Potential of miRNAs, lncRNAs and circRNAs.
Review in Molecular diagnosis & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Connective tissue diseases (CTDs) are a heterogeneous group of disorders characterized by structural and functional impairment of the extracellular matrix, manifesting primarily as autoimmune, heritable or degenerative conditions such as systemic lupus erythematosus (SLE), osteogenesis imperfecta (OI) and abdominal aortic aneurysm (AAA). In SLE, lupus nephritis remains a leading cause of morbidity and a major determinant of long-term outcomes. Recent advances in transcriptomics and epigenomics have revealed non-coding RNAs (ncRNAs), including microRNA (miRNAs), long non-coding RNA (lncRNAs) and circular RNA (circRNAs), as pivotal regulators of gene expression, immune responses and tissue remodeling. Their tissue-specific expression profiles, molecular stability and involvement in key pathogenic pathways make them promising candidates for diagnostic biomarkers and therapeutic interventions. In this review, we summarize current knowledge of the roles of ncRNAs in CTDs, focusing on their regulatory mechanisms in immune dysregulation, extracellular matrix homeostasis and cell fate determination. Furthermore, we highlight their diagnostic potential in liquid biopsy approaches and discuss therapeutic strategies employing RNA mimics, inhibitors and antisense oligonucleotides. Finally, we address future perspectives, including the integration of multi-omics approaches and targeted delivery systems, which may accelerate the translation of ncRNA-based therapies into clinical practice.
Indexed as
Identifiers
41697527What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.